Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
- PMID: 33475702
- PMCID: PMC8892260
- DOI: 10.1001/jama.2021.0600
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
Conflict of interest statement
Similar articles
-
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33444297 Free PMC article.
-
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.Am J Transplant. 2021 Mar;21(3):1332-1337. doi: 10.1111/ajt.16516. Am J Transplant. 2021. PMID: 33641264 Free PMC article. Review. No abstract available.
-
Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.JAMA Netw Open. 2021 Aug 2;4(8):e2122255. doi: 10.1001/jamanetworkopen.2021.22255. JAMA Netw Open. 2021. PMID: 34463744 Free PMC article.
-
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33507892 Free PMC article.
-
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.Am J Transplant. 2021 Mar;21(3):1326-1331. doi: 10.1111/ajt.16517. Am J Transplant. 2021. PMID: 33641268 Free PMC article. Review. No abstract available.
Cited by
-
How a Novel Approach of Allergy Call Center Improved the Management of the Anti-COVID Vaccination Campaign in Piedmont: Italy.J Epidemiol Glob Health. 2024 Oct 14. doi: 10.1007/s44197-024-00309-2. Online ahead of print. J Epidemiol Glob Health. 2024. PMID: 39400652
-
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.Vaccines (Basel). 2024 Sep 17;12(9):1059. doi: 10.3390/vaccines12091059. Vaccines (Basel). 2024. PMID: 39340089 Free PMC article.
-
COVID-19 vaccines: anaphylaxis and anxiety : A case study from an allergy unit.Wien Klin Wochenschr. 2024 Nov;136(21-22):590-597. doi: 10.1007/s00508-024-02435-0. Epub 2024 Sep 11. Wien Klin Wochenschr. 2024. PMID: 39259224 Free PMC article.
-
Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty®) COVID-19 Vaccination Successfully Treated with Cemiplimab.Viruses. 2024 Aug 6;16(8):1260. doi: 10.3390/v16081260. Viruses. 2024. PMID: 39205234 Free PMC article.
-
Physiological Response to the COVID-19 Vaccine: Insights From a Prospective, Randomized, Single-Blinded, Crossover Trial.J Med Internet Res. 2024 Jul 31;26:e51120. doi: 10.2196/51120. J Med Internet Res. 2024. PMID: 39083770 Free PMC article. Clinical Trial.
References
-
- FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised January 2021. Accessed January 17, 2021. https://www.fda.gov/media/144413/download
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
